TAVALISSE® (fostamatinib disodium hexahydrate) tablets

TAVALISSE® (fostamatinib disodium hexahydrate) is the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Click for information on TAVALISSE
Click for Full Prescribing Information

REZLIDHIA (olutasidenib) capsules

REZLIDHIA (olutasidenib) capsules are indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.

Click for information on REZLIDHIA
Click for Full Prescribing Information*

*Including Boxed WARNING for differentiation syndrome